Chesapeake Capital Corp IL Acquires New Holdings in Merck & Co., Inc. $MRK

Chesapeake Capital Corp IL acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,710 shares of the company’s stock, valued at approximately $917,000.

Other institutional investors also recently bought and sold shares of the company. D.A. Davidson & CO. grew its holdings in Merck & Co., Inc. by 4.4% in the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after purchasing an additional 24,576 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Merck & Co., Inc. by 48.9% in the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after purchasing an additional 32,114 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Merck & Co., Inc. by 12.7% in the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after purchasing an additional 13,940 shares during the last quarter. NEOS Investment Management LLC grew its holdings in Merck & Co., Inc. by 39.9% in the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock worth $29,181,000 after purchasing an additional 99,074 shares during the last quarter. Finally, Campbell Capital Management Inc. purchased a new position in Merck & Co., Inc. in the third quarter worth $1,866,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. This represents a 63.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. This trade represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Trading Down 0.9%

Shares of Merck & Co., Inc. stock opened at $111.26 on Friday. The firm has a 50-day simple moving average of $117.07 and a two-hundred day simple moving average of $108.31. The company has a market cap of $274.78 billion, a P/E ratio of 31.34, a price-to-earnings-growth ratio of 2.53 and a beta of 0.18. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.30 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. UBS Group lifted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Friday, February 13th. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Merck & Co., Inc. in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.